<p>隨着美國股市逐漸上漲，標準普爾 500 指數達到新高，投資者密切關注美聯儲的信號和可能影響未來趨勢的主要科技公司財報。在這樣的背景下，便士股票——通常代表較小或較新的公司——繼續為那些尋求低價增長機會的投資者提供引人注目的機會。儘管被視為一個小眾領域，這些股票在擁有良好的財務健康和基本面時可以大放異彩，展現出潛在的上行空間，同時降低一些相關風險。</p>
<h3>美國十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.86</td>
<td>$591.48M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.67</td>
<td>$614.83M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8033</td>
<td>$141.11M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.95</td>
<td>$499.74M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.40</td>
<td>$931.68M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9301</td>
<td>$6.69M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.75</td>
<td>$88.13M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.90</td>
<td>$12.14M</td>
<td>✅ 2 ⚠️ 4 查看分析 </td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國便士股票篩選器中的 326 只股票的完整列表。</p>
<p>讓我們回顧一些我們篩選出的顯著股票。</p>
<h2>Definitive Healthcare (DH)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Definitive Healthcare Corp. 提供一個 SaaS 醫療商業智能平台，業務遍及美國和國際市場，市值為 3.4563 億美元。</p>
<p><strong>運營：</strong> 該公司從其互聯網信息提供商部門產生的收入為 2.4228 億美元。</p>
<p><strong>市值：</strong> 3.4563 億美元</p>
<p>Definitive Healthcare Corp. 的市值為 3.4563 億美元，運營一個 SaaS 醫療平台，儘管被認為是虧損的，但由於正的自由現金流，保持着超過三年的強現金流。該公司已成功用其資產覆蓋短期和長期負債，儘管近期出現虧損，但顯示出財務穩定性。其交易價格低於估計公允價值的 55%，與同行相比顯示出良好的相對價值。最近的財報顯示，與之前的時期相比，虧損有所減少，但短期內仍難以實現盈利。近期的股票回購並未顯著稀釋股東價值。</p>
<ul>
<li>點擊探索我們在 Definitive Healthcare 財務健康報告中的詳細發現。</li>
<li>通過我們的公司盈利預估報告，獲取 Definitive Healthcare 的前景和預期表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/814e07d4-65b6-4122-8c7a-d215d747d83a/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/814e07d4-65b6-4122-8c7a-d215d747d83a/chart/financial-position-analysis"/></p>
<p>DH 財務狀況分析截至 2026 年 1 月</p>
<h2>Duluth Holdings (DLTH)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Duluth Holdings Inc. 在美國運營，銷售男女休閒服、工作服、户外服裝及配飾，市值為 8,888 萬美元。</p>
<p><strong>運營：</strong> 該公司的在線零售收入為 5.9056 億美元。</p>
<p><strong>市值：</strong> 8,888 萬美元</p>
<p>Duluth Holdings Inc. 的市值為 8,888 萬美元，面臨挑戰，因為它仍處於虧損狀態，並且在過去五年中虧損有所增加。儘管如此，該公司的短期資產超過其短期和長期負債，顯示出一定的財務穩定性。最近的財報顯示，與之前的時期相比，虧損有所減少，儘管銷售額同比下降。該公司下調了 2026 財年的淨銷售指導，反映出持續的運營困難。雖然交易價格幾乎低於估計公允價值的 90%，顯示出潛在的上行空間，但高波動性和現金流覆蓋債務不足仍然是投資者的擔憂。</p>
<ul>
<li>通過我們的綜合資產負債表健康報告，深入瞭解 Duluth Holdings 的複雜性。</li>
<li>通過審查我們的增長報告，瞭解 Duluth Holdings 的盈利前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d0c3e16-87e8-4d03-84ca-6ae8fb4fd0fb/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d0c3e16-87e8-4d03-84ca-6ae8fb4fd0fb/chart/financial-position-analysis"/></p>
<p>DLTH 財務狀況分析截至 2026 年 1 月</p>
<h2>Prelude Therapeutics (PRLD)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家臨牀階段的精準腫瘤學公司，致力於為服務不足的患者發現和開發新型癌症藥物，市值為 1.6727 億美元。</p>
<p><strong>運營：</strong> 該公司從其生物技術（初創企業）部門產生的收入總計為 1050 萬美元。</p>
<p><strong>市值：</strong> 1.6727 億美元</p>
<p>Prelude Therapeutics 的市值為 1.6727 億美元，專注於精準腫瘤學領域，儘管在 2025 年第三季度報告了 650 萬美元的銷售額，但仍未產生收入。該公司無債務，短期資產超過負債，但由於波動性增加和截至 2025 年 9 月的現金流僅有七個月，面臨挑戰。最近的戰略舉措包括通過私募融資籌集 2500 萬美元，以及與 Incyte 達成其 JAK2V617F 抑制劑項目的獨家選擇協議。儘管未盈利，但預計收益將以每年 55.66% 的速度顯著增長，在高波動性中展現出潛在機會。</p>
<ul>
<li>在我們的財務健康報告中更詳細地瞭解 Prelude Therapeutics 的潛力。</li>
<li>通過審查我們的增長報告，獲取 Prelude Therapeutics 未來方向的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/financial-position-analysis"/></p>
<p>PRLD 財務狀況分析截至 2026 年 1 月</p>
<h2>接下來該怎麼辦？</h2>
<ul>
<li>解鎖更多寶藏！我們的美國便士股票篩選器為您挖掘了 323 家更多公司供您探索。點擊這裏揭開我們精心策劃的 326 只美國便士股票名單。</li>
<li>尋找替代機會？我們發現 13 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整名單，免費獲取。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容為一般性信息。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

<p>隨着美國股市的上漲，低價股吸引了投資者的關注。Definitive Healthcare 的市值為 3.4563 億美元，運營着一個 SaaS 醫療平台，儘管尚未盈利，但顯示出財務穩定性。Duluth Holdings 的市值為 8,888 萬美元，面臨着損失增加和銷售下滑的挑戰。Prelude Therapeutics 是一家臨牀階段的腫瘤學公司，市值為 1.6727 億美元，尚未產生收入，但儘管現金流有限，仍具有增長潛力。投資者被鼓勵探索更多低價股以尋找增長機會</p>

<p>As the U.S. stock market edges higher with the S&amp;P 500 reaching new milestones, investors are keenly watching for signals from the Federal Reserve and major tech earnings that could influence future trends. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for those seeking growth at lower price points. Though considered a niche area, these stocks can shine when backed by solid financial health and fundamentals, presenting potential upside while mitigating some of the associated risks.</p>
<div class="lb-trans"><p>隨着美國股市逐漸上漲，標準普爾 500 指數達到新高，投資者密切關注美聯儲的信號和可能影響未來趨勢的主要科技公司財報。在這樣的背景下，便士股票——通常代表較小或較新的公司——繼續為那些尋求低價增長機會的投資者提供引人注目的機會。儘管被視為一個小眾領域，這些股票在擁有良好的財務健康和基本面時可以大放異彩，展現出潛在的上行空間，同時降低一些相關風險。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.86</td>
<td>$591.48M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.67</td>
<td>$614.83M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8033</td>
<td>$141.11M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.95</td>
<td>$499.74M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.40</td>
<td>$931.68M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9301</td>
<td>$6.69M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.75</td>
<td>$88.13M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.90</td>
<td>$12.14M</td>
<td>✅ 2 ⚠️ 4 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.86</td>
<td>$591.48M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.67</td>
<td>$614.83M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8033</td>
<td>$141.11M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.95</td>
<td>$499.74M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.17</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.40</td>
<td>$931.68M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.9301</td>
<td>$6.69M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.75</td>
<td>$88.13M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Universal Safety Products (UUU)</td>
<td>$4.90</td>
<td>$12.14M</td>
<td>✅ 2 ⚠️ 4 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 326 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國便士股票篩選器中的 326 只股票的完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>讓我們回顧一些我們篩選出的顯著股票。</p>
</div><h2>Definitive Healthcare (DH)</h2>
<div class="lb-trans"><h2>Definitive Healthcare (DH)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Definitive Healthcare Corp. offers a SaaS healthcare commercial intelligence platform operating both in the United States and internationally, with a market cap of $345.63 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Definitive Healthcare Corp. 提供一個 SaaS 醫療商業智能平台，業務遍及美國和國際市場，市值為 3.4563 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $242.28 million from its Internet Information Providers segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其互聯網信息提供商部門產生的收入為 2.4228 億美元。</p>
</div><p><strong>Market Cap:</strong> $345.63M</p>
<div class="lb-trans"><p><strong>市值：</strong> 3.4563 億美元</p>
</div><p>Definitive Healthcare Corp., with a market cap of US$345.63 million, operates a SaaS healthcare platform and is considered unprofitable, yet maintains a strong cash runway exceeding three years due to positive free cash flow. The company has managed to cover both short-term and long-term liabilities with its assets, suggesting financial stability despite recent losses. It trades at 55% below estimated fair value and shows good relative value compared to peers. Recent earnings reports indicate reduced losses compared to previous periods, but profitability remains elusive in the near term. Share buybacks have not significantly diluted shareholder value recently.</p>
<div class="lb-trans"><p>Definitive Healthcare Corp. 的市值為 3.4563 億美元，運營一個 SaaS 醫療平台，儘管被認為是虧損的，但由於正的自由現金流，保持着超過三年的強現金流。該公司已成功用其資產覆蓋短期和長期負債，儘管近期出現虧損，但顯示出財務穩定性。其交易價格低於估計公允價值的 55%，與同行相比顯示出良好的相對價值。最近的財報顯示，與之前的時期相比，虧損有所減少，但短期內仍難以實現盈利。近期的股票回購並未顯著稀釋股東價值。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Definitive Healthcare's financial health report.</li>
<li>Gain insights into Definitive Healthcare's outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 Definitive Healthcare 財務健康報告中的詳細發現。</li>
<li>通過我們的公司盈利預估報告，獲取 Definitive Healthcare 的前景和預期表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/814e07d4-65b6-4122-8c7a-d215d747d83a/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/814e07d4-65b6-4122-8c7a-d215d747d83a/chart/financial-position-analysis"/></p>
<p>DH Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>DH 財務狀況分析截至 2026 年 1 月</p>
</div><h2>Duluth Holdings (DLTH)</h2>
<div class="lb-trans"><h2>Duluth Holdings (DLTH)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Duluth Holdings Inc. operates in the United States, selling casual wear, workwear, outdoor apparel, and accessories for men and women with a market capitalization of $88.88 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Duluth Holdings Inc. 在美國運營，銷售男女休閒服、工作服、户外服裝及配飾，市值為 8,888 萬美元。</p>
</div><p><strong>Operations:</strong> The company's revenue from online retailing amounts to $590.56 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的在線零售收入為 5.9056 億美元。</p>
</div><p><strong>Market Cap:</strong> $88.88M</p>
<div class="lb-trans"><p><strong>市值：</strong> 8,888 萬美元</p>
</div><p>Duluth Holdings Inc., with a market cap of US$88.88 million, faces challenges as it remains unprofitable and has seen increased losses over the past five years. Despite this, the company's short-term assets exceed both its short and long-term liabilities, indicating some financial stability. Recent earnings reports show reduced losses compared to previous periods, though sales have declined year-over-year. The company lowered its net sales guidance for fiscal 2026, reflecting ongoing operational difficulties. While trading at nearly 90% below estimated fair value suggests potential upside, high volatility and insufficient cash flow coverage of debt remain concerns for investors.</p>
<div class="lb-trans"><p>Duluth Holdings Inc. 的市值為 8,888 萬美元，面臨挑戰，因為它仍處於虧損狀態，並且在過去五年中虧損有所增加。儘管如此，該公司的短期資產超過其短期和長期負債，顯示出一定的財務穩定性。最近的財報顯示，與之前的時期相比，虧損有所減少，儘管銷售額同比下降。該公司下調了 2026 財年的淨銷售指導，反映出持續的運營困難。雖然交易價格幾乎低於估計公允價值的 90%，顯示出潛在的上行空間，但高波動性和現金流覆蓋債務不足仍然是投資者的擔憂。</p>
</div><ul>
<li>Navigate through the intricacies of Duluth Holdings with our comprehensive balance sheet health report here.</li>
<li>Understand Duluth Holdings' earnings outlook by examining our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的綜合資產負債表健康報告，深入瞭解 Duluth Holdings 的複雜性。</li>
<li>通過審查我們的增長報告，瞭解 Duluth Holdings 的盈利前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0d0c3e16-87e8-4d03-84ca-6ae8fb4fd0fb/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/0d0c3e16-87e8-4d03-84ca-6ae8fb4fd0fb/chart/financial-position-analysis"/></p>
<p>DLTH Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>DLTH 財務狀況分析截至 2026 年 1 月</p>
</div><h2>Prelude Therapeutics (PRLD)</h2>
<div class="lb-trans"><h2>Prelude Therapeutics (PRLD)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing novel cancer medicines for underserved patients, with a market cap of $167.27 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家臨牀階段的精準腫瘤學公司，致力於為服務不足的患者發現和開發新型癌症藥物，市值為 1.6727 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its Biotechnology (Startups) segment, totaling $10.5 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其生物技術（初創企業）部門產生的收入總計為 1050 萬美元。</p>
</div><p><strong>Market Cap:</strong> $167.27M</p>
<div class="lb-trans"><p><strong>市值：</strong> 1.6727 億美元</p>
</div><p>Prelude Therapeutics, with a market cap of US$167.27 million, operates in the precision oncology space and remains pre-revenue despite reporting US$6.5 million in sales for Q3 2025. The company is debt-free with short-term assets exceeding liabilities, yet faces challenges due to increased volatility and a limited cash runway of seven months as of September 2025. Recent strategic moves include a private placement raising US$25 million and an exclusive option agreement with Incyte for its JAK2V617F inhibitor program. Despite unprofitability, earnings are forecasted to grow significantly at 55.66% annually, presenting potential opportunities amidst high volatility.</p>
<div class="lb-trans"><p>Prelude Therapeutics 的市值為 1.6727 億美元，專注於精準腫瘤學領域，儘管在 2025 年第三季度報告了 650 萬美元的銷售額，但仍未產生收入。該公司無債務，短期資產超過負債，但由於波動性增加和截至 2025 年 9 月的現金流僅有七個月，面臨挑戰。最近的戰略舉措包括通過私募融資籌集 2500 萬美元，以及與 Incyte 達成其 JAK2V617F 抑制劑項目的獨家選擇協議。儘管未盈利，但預計收益將以每年 55.66% 的速度顯著增長，在高波動性中展現出潛在機會。</p>
</div><ul>
<li>Take a closer look at Prelude Therapeutics' potential here in our financial health report.</li>
<li>Gain insights into Prelude Therapeutics' future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的財務健康報告中更詳細地瞭解 Prelude Therapeutics 的潛力。</li>
<li>通過審查我們的增長報告，獲取 Prelude Therapeutics 未來方向的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/financial-position-analysis"/></p>
<p>PRLD Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>PRLD 財務狀況分析截至 2026 年 1 月</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下來該怎麼辦？</h2>
</div><ul>
<li>Unlock more gems! Our US Penny Stocks screener has unearthed 323 more companies for you to explore.Click here to unveil our expertly curated list of 326 US Penny Stocks.</li>
<li>Looking For Alternative Opportunities? We've found 13 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖更多寶藏！我們的美國便士股票篩選器為您挖掘了 323 家更多公司供您探索。點擊這裏揭開我們精心策劃的 326 只美國便士股票名單。</li>
<li>尋找替代機會？我們發現 13 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整名單，免費獲取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容為一般性信息。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

Definitive Healthcare 及其他兩個有前景的便士股